Sarah A. Kagan discusses the potential impact of the Federal Circuit’s decision invalidating patents on Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra in Law360.
Ms. Kagan authored an amicus brief that BIO filed in the case.
Click here to read the article, “Fed. Circ. Ruling Takes ‘Blocking Patents’ To New Places.”
Posted: September 19, 2018
